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Available online xxxxMost cancer cells exacerbate the pentose phosphate pathway (PPP) to enhance biosynthetic precursors and antioxidant
defenses. Metformin, which is used as a first-line oral drug for the treatment of type 2 diabetes, has been proposed to
inhibit the malignant progression of different types of cancers. However, metformin has shown poor efficacy as single
agent in several clinical trials. Thus, the aim of the present work was to investigate whether the pharmacological inhi-
bition of G6PDH, the first and rate-limiting enzyme of the PPP, by 6-amino nicotinamide (6-AN) potentiates the anti-
tumoral activity of metformin on different human melanoma cell lines. Our results showed that 6-AN has sensitizing
properties to metformin cytotoxicity. The combination of metformin and 6-AN decreased glucose consumption and
lactate production, altered the mitochondrial potential and redox balance, and thereby blocked melanoma cell pro-
gression, directing cells to apoptosis and necrosis. To our knowledge, this is the first study describing the effect of
this combination. Future preclinical studies should be performed to reveal the biological relevance of this finding.Keywords:
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Despite the efforts of new therapeutics development, including BRAF in-
hibitors and immunomodulators (as anti-PDL1 and anti-CTLA-4), metasta-
tic melanoma remains to be the principal life-threating skin cancer [1,2].
Cancer cell metabolism is particularly characterized by the Warburg effect
[3,4] which includes an exacerbation of glucose consumption accompanied
by an increase in lactate production. Thus, cancer cell metabolism appears
as an attractivefield for the development of clinical and pre-clinical therapy
[5,6]. Beyond glycolysis, the second most important fate of intracellular
glucose is the pentose phosphate pathway (PPP). This pathway enables can-
cer cells to adapt to anabolic demands that require rapid DNA, RNA, and
lipid synthesis and to oxidative cellular stress [7,8]. The inhibition of key
enzymes of the PPP, including glucose-6-phosphate dehydrogenase
(G6PDH), strongly affects the malignant proliferation and metastases of
cancer cells both in vitro and in vivo [9]. In many human cancers, G6PDH
is upregulated and correlates with poor prognosis [10]. Interestingly, the
inhibition of G6PDH restores the sensitivity of cancer cells to chemotherapy
[11]. Therefore, the inhibition of the PPP has been proposed as an attractive
therapeutic strategy against cancer.. Villaverde).
vier Inc. on behalf of Neoplasia PMetformin is a biguanide anti-diabetic drug, which is clinically known
as orally well tolerated that has been approved by the Food and Drug Ad-
ministration (FDA). Retrospective epidemiological studies have revealed a
decrease in the incidence of cancer in diabetic patients treated with metfor-
min [12,13]. Metformin modulates cell metabolism at different cell levels
by increasing glycolysis, inhibiting respiratory chain complex I and ulti-
mately inhibitingmTORpathway. This leads to growth arrest and apoptosis
[14,15]. Interestingly, metformin has been shown to decrease cancer cell
viability and tumor growth in different preclinical models [16–18], inhibit
the malignant progression of oral premalignant lesions in chemically-
induced experimental models [19] and diminish tumor growth in human
head and neck squamous cell carcinoma xenografts [19]. However, metfor-
min seems to have low efficacy as monotherapy against a number of differ-
ent tumors, including melanoma [20]. Thus, the potential adjuvant role of
metformin is currently being investigated in several clinical trials
[5,16,21–24] and, high efforts are being made to improve metformin
performance.
Despite the fact that metformin cytotoxicity may be in part mediated by
ROS increase [25,26], the role of the pentose phosphate pathway during
metformin treatment remains to be investigated. In this context, the aimress, Inc. This is an open access article under the CC BY-NC-ND license (http://
M.F. Arbe et al. Translational Oncology 13 (2020) 100842of this study was to investigate whether metformin and the G6PDH inhibi-
tor 6-amino nicotinamide (6-AN) synergize to kill malignant melanoma
cells and determine themechanisms underlying this combinatory approach
and its significance regarding the antitumor response against melanoma.
Materials and methods
Cell culture
Cells hM1, hM2, hM4, hM9 and hM10were established frommelanoma
patients of Instituto de Oncología Ángel H. Roffo, Facultad de Medicina,
Universidad de Buenos Aires, as it was previously described [27]. Also,
we used other human melanoma cell lines as A375 (ATCC® CRL-1619™),
SB2 [28] and M8 [29]. Cells were cultured at 37 °C in a humidified atmo-
sphere of 95% air and 5% CO2 with DMEM/F12 medium (Invitrogen,
Carlsbad, CA, USA) containing 10% FBS (Internegocios, Córdoba,
Argentina), 10 mM HEPES (pH 7.4) and antibiotics (60 mg/L Penicillin G,
50 mg/L Streptomycin and 50 mg/L Gentamicin). 3D culture. Multicellu-
lar spheroids were obtained following the procedure of hanging drop cul-
ture [30] from trypsinized monolayers (0.8–1.4 × 104 cell/spheroid).
Viability. Cells were seeded onto 96-well plates at 4–7 × 103 cells/well
24 h before treatments. After 5 days of treatments, cell viability was mea-
sured by acidic phosphatase assay [31] and crystal violet staining [32].
Combination studies. Cells were treatedwith amedium containing a com-
bination of different concentrations of MET (0.1–10 nM) and a fixed con-
centration of 6-AN (50 μM) or a combination of different concentrations
of 6-AN (0.01–100 μM) and a fixed concentration of MET (5 nM). To eval-
uate the possible effect between the combination of 6-AN andMET was de-
termined using both CompuSyn and Combenefit software [33–35]. The
three possibilities: CI < 1, CI = 1, and CI > 1, indicated synergy, additive
effect, and antagonism, respectively.
Glucose and lactate content in cell culture media
After 48 h of treatments, 5 μL of each supernatant was transferred to a
new 96-well plate. Then, the concentration of glucose and lactate was de-
termined colorimetrically by specific commercial kits (Weiner Lab. and
Cobas Roche, respectively).
Western blotting
(i) Whole-cell extracts were obtained using a lysis and extraction buffer
(50mM tris-HCl (pH 8); 100mM NaCl; 1% Triton; 10mM EDTA; protease
inhibitor 1:10,000). The lysates were centrifuged at 10,000 rpm for
10min at 4 °C, and the supernatant was stored at−20 °C until immunoblot-
ting was performed. Protein content was determined by the Bradford
method. (ii) Immunoblot. Proteins (70–100 μg) from whole-cell extracts
were electrophoresed on SDS-PAGE and transferred to PVDF membranes.
The membrane was blocked with 5% nonfat milk for 1 h, incubated with
the primary antibody overnight at 4 °C and exposed to corresponding sec-
ondary antibody (1:5000) for 1 h at room temperature. The primary anti-
bodies used were GLUT-1 (Abcam 115,730), PCNA (PC10, Cell-Signaling
2586) and PARP (46D11, Cell-Signaling 9532). Densitometry units were re-
ferred to β-actin (8H10D10, Cell-Signaling 3700). The secondary antibod-
ies used were goat anti-rabbit IgG-HRP (Sigma A9169) and goat anti-
mouse IgG-HRP (Santa Cruz sc-2031). (iii) Detection. The chemilumines-
cence was detected using the Image Quant LAS 500 (GE Healthcare Life
Sciences).
Immunofluorescence assay
Immunofluorescence imaging was performed to determine the expres-
sion of the proliferative marker Ki67 of treated melanoma cells for 48 h
and controls. Cells were fixed with fixation solution (2% formaldehyde -
0,2% glutaraldehyde) for 10 min. For immunostaining, the cells were
permeabilized for 30min in 0.1% Triton X–100 and incubated for 1h2
with a blocking solution containing 1% BSA, 0.1% Triton X–100 and
0.3M glycine in PBS. After overnight incubation with primary antibody so-
lution (Ki67, Abcam 15580; γH2AX, 11174 Abcam) at 4°C, the secondary
antibody (1:1000, Abcam 150077) was added for 1 h at room temperature.
To counterstain the nuclei, the coverslips were mounted with Fluoroshield
Mounting Medium with DAPI (Abcam 104139). The images were acquired
with a Nikon Eclipse™ TE2000-5 inverted fluorescence microscope and
photographed with a Nikon DS-Fi1 digital camera at 400 magnification.
The objective used was Nikon Plan Fluor ELWD 40× Ph2 DM.
Measurement of cellular production of reactive oxygen species (ROS) (i.e. intra-
cellular oxidants) and mitochondrial membrane potential
After treatments, cells were harvested and incubated with 0.5 μM 2′,7′-
dichlorodihydrofluorescein diacetate (DCF, Invitrogen) and 50 nM
tetramethylrhodamine, methyl ester (TMRM, Invitrogen) in DMEM-F12
medium without FBS for 30 min. Then, cells were subjected to multiple-
channel flow cytometry on a PARTEC PASS III at the Flow Cytometry Facil-
ity of the IDEHU (Instituto de Estudios de la Inmunidad Humoral, Buenos
Aires, Argentina). The final data were analyzed using the Flowing software
(2.5.1, Finland) and the medium intensity of fluorescence was calculated
(Geometric Mean: Gm).
Determination of granularity or internal complexity of melanoma cells
The cell complexity of control untreated cells was analyzed by physical
parameter by flow cytometry. Side scatter is a measure of the cell refractive
index that depends on the cell granularity or internal complexity.
Bromodeoxyuridine labeling
Cells were grown and labeledwith a thymidine analog BrdU for 48 h to-
gether with treatments. The complete medium of monolayer was replaced
with medium containing 40 μM 5-Bromo-2′-deoxyuridine (Sigma), 5 μM
uridine (Sigma) and 0.4 μM 5-fluoro-2′-deoxyuridine (Sigma). After treat-
ments, the cells were fixed with fixation solution (2% formaldehyde -
0,2% glutaraldehyde) for 10 min. Then, samples were digested by Hind
lll on React 2 buffer (Gibco) and Eco Rl on SH buffer (Sigma) for 1 h to cre-
ate single-stranded regions in the DNA and to expose the incorporation of
BrdU to the monoclonal mouse antibody [36]. After this, the samples
were finished as previously described in a conventional immunofluores-
cence assay. Results are expressed as an index of BrdU positive nuclei rela-
tive to total number of nuclei.
Annexin V/propidium iodide labeling
The binding of annexin V to externalized phosphatidylserine was used
as a measurement of the number of apoptotic cells with an FITC Annexin
V Apoptosis Detection Kit II (BD Biosciences) according to the manufactur-
er's instructions. The samples were analyzed by flow cytometry as previ-
ously described and the results are presented as the percentage of cells
that were viable (Annexin V and PI negative), early apoptotic (Annexin V
positive but PI negative), late apoptotic (Annexin V and PI positive) or ne-
crotic cells (Annexin V negative and PI positive).
Acridine orange/ethidium bromide staining
Melanoma cells treated for 72 h were incubated with acridine orange
(10 μg/mL, green) and ethidium bromide (10 μg/mL, red) for 1 min and
staining was evaluated by epifluorescent microscopy (Nikon Eclipse™
E400 fluorescence microscope and photographed with a Nikon Coolpix®
995 digital camera at 400 magnification, objective: Plan Fluor 40× DIC
M). The co-localization of both stains indicates late apoptotic or necrotic
events (orange/red).
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Cells were suspended in culture medium and the suspension was frozen
at −20 °C until use (maximum two months). The frozen suspensions were
sonicated at 100 W in 50% cycle at 4 °C using a VibraCell sonicator model
600 W (Sonics &Materials Inc., Newton, USA) for 4 min. After centrifuga-
tion of the homogenate (10,000 ×g, 20 min, 4 °C), the supernatants were
collected and maintained at 4 °C during enzyme assays. Enzyme activity
was measured in a Shimadzu spectrophotometer model UV-160 (Shimadzu
Corporation, Tokyo, Japan). The protocols described by Kitto (1969) and
Alp (1976) were used for the determination of malate dehydrogenase activ-
ity and NADP dependent isocitrate dehydrogenase activity, respectively.
NADP dependent malate dehydrogenase activity was measured according
to Brook's (1978) protocol [37,38]. Glucose 6-P dehydrogenase activity
was determined with Kornberg and Horecker assays (1955).
Statistics
All experiments were performed at least in triplicate and data are
expressed as the mean ± SEM. Differences between groups were analyzed
with one- or two-way ANOVA followed by multiple comparisons Tukey's
test. p < .05 was established as significant. Analyses were made using
INFOSTAT free edition and GraphPad Prism 6 software (GraphPad Soft-
ware Inc., USA).
Results
6-AN potentiated the cytotoxic effects of metformin
The inhibition of glycolysis, the main glucose metabolism pathway, is
known to potentiate the effect of metformin (MET) [25,39,40]. Since glu-
cose is also highly metabolized by the PPP, we investigated whether the in-
hibition of G6PDH, the key enzyme of the PPP, could sensitize melanoma
cells to MET. Eight human melanoma cell lines were treated with 5 mM
of MET, 50 μM of 6-AN, or a combination of both (MET/6-AN). After five
days of treatment, the effect was visualized by crystal violet (CV) staining.
The viability of all the melanoma cell lines evaluated was highly affected
by the combination of MET/6-AN that showed almost negative CV staining
(Fig. 1A). This effect was even observed in the M8 cell line, whose viability
was not affected by the individual treatments. Since spheroids better resem-
ble the tumor architecture, we further evaluated the effect ofMET/6-AN on
melanoma cells growing as multicellular spheroids. After 14 days of treat-
ment, MET/6-AN combination was also effective in decreasing spheroids
size and disaggregating them (Fig. 1B).
To further evaluate this combinatory strategy, we incubated melanoma
cells with a fixed concentration of 6-AN (50 μM) and variable concentra-
tions of MET (0.1–10 mM). After five days of treatment, 1 mM MET was
enough to significantly potentiate the effect of 6-AN in five out of the
eight melanoma cell lines evaluated (62.5%, p < .05; hM1, hM2, hM9,
hM10 and SB2), whereas 2.5 mM MET was necessary for the other three
cell lines (hM4, M8 and A375) (Fig. 1C). The significant changes in the
IC50s values (p < .05, Fig. 1D) demonstrated that 6-AN improved the
in vitro potency of MET.
Next, we used two different software applications to analyze the extent
of the combinatory effect of MET/6-AN. The Combination Index (CI) de-
scribed by Chou-Talalay was determined by using CompuSyn software.
We found thatMET and 6-AN combination resulted in a CI<1 thus indicat-
ing a synergist effect for all the evaluated cell lines (A375, hM1 and hM4).
This result was also depicted by Loewe curves from Combenefit software,
where blue areas show synergistic combinations as it is shown in Fig. 1E.
MET/6-AN treatment decreased the proliferation index of melanoma cells
Aggressive melanomas are characterized by a high proliferation index.
Thus, we next evaluated Ki67 nuclei by labeling A375, hM1 and hM4 mel-
anoma cells after 48 h of treatments. We found no significant differences3
between controls and any of the MET-treated cell lines evaluated
(Fig. 2A). In addition, inhibition of G6PDH by 6-AN only decreased the
Ki67 rate of the highly sensitive hM1 melanoma cell line from 0.73 to
0.65 (Fig. 2A, p < .05), without affecting the other cell lines. Notably,
the proliferation index was affected by MET/6-AN combination in all cell
lines as shown by the decrease in the number of positive nuclei (white ar-
rows) (Fig. 2A). The quantification of Ki67-positive nuclei indicated that
hM1 presented a highly antiproliferative response towards MET/6-AN
combination, with an almost complete decrease in the Ki67 rate from
0.73 to 0.1 (~90%, Fig. 2B, p < .01). Consistently, the western blotting
assay showed a mildly decrease in the proliferating cell nuclear antigen
(PCNA) content caused by the MET/6-AN treatment, in hM1 (Fig. 2B, p
< .05). Then, we further investigated the proliferation capacity of hM1
cells by the bromodeoxyuridine (BrdU) incorporation rate. In agreement
with the results of Ki67 and PCNA, the proliferation capacity of hM1 was
affected both by 6-AN and MET/6-AN combination, to a higher extent
(Fig. 2C).
MET/6-AN increased late apoptotic/necrotic events
Once we had demonstrated that the MET/6-AN combinatory approach
decreased the proliferation index, wemoved one step forward and used the
double staining acridine orange/ethidium bromide (AO/EB) to allow the
observation of apoptotic/necrotic events. The cell membrane is permeable
to acridine orange (green) whereas ethidium bromide (red) enters only in
late apoptotic or necrotic cells. After 72 h of treatments, A375, hM1 and
hM4 control cells or treated with 6-AN mostly appeared as green-stained
healthy cells (Fig. 3A). In contrast, MET and MET/6-AN treatments in-
creased the number of late apoptotic/necrotic cells as evidenced by the in-
crease in the number of red-stained nuclei and apoptotic bodies (white and
dashed arrows respectively). Interestingly,whereas red nuclei staining after
MET treatment as single agent appeared among apparently green healthy
cells, after the MET/6-AN combination, red nuclei appeared among notori-
ously affected (shrinkage and blebbing) remaining cells. To quantify this
process, melanoma cells were analyzed by Flow cytometry for binding of
annexin V to exteriorized phosphatidylserine. MET/6-AN increased the
number of double-stained positive cells either highly (3- to 4-fold in A375
and hM1, respectively) or mildly (hM4), thus denoting an increase in the
number of late apoptotic events (Fig. 3B). We found no significant increase
in annexin V exposure after MET or 6-AN as monotherapies in any of the
cell lines evaluated.
Next, necrosis was also evaluated by propidium iodide (PI) uptake. hM1
and A375 cell lines exhibited a loss of membrane integrity denoted by an
increase in PI uptake after 48 h of treatment with MET and MET/6-AN.
These results were accompanied by an increase in the number of subG0
events after MET/6-AN treatment in A375 and hM1 but not in hM4
(Fig. 3C).
Finally, we also found an increase in cleaved Poly-(ADP-ribose) poly-
merase, a proapoptotic protein, after MET and MET/6-AN treatment com-
pared to control, especially in hM1 melanoma cells (Fig. 3D).
Effects of MET/6-AN on metabolic parameters
To understandwhichmechanismswere underlying the antiproliferative
and cytotoxic effects of MET/6-AN, we further investigate whether this
combination was affecting glucose consumption and lactate production,
both of which are particularly exacerbated in cancer cells.
Independently of cell sensitiveness, the color of the cell culture medium
suggested that 6-AN and MET/6-AN decreased extracellular acidification,
whereas MET increased (Fig. 4A). In agreement, we found that 6-AN signif-
icantly decreased the presence of lactate in the supernatant of all cell lines
(Fig. 4B, gray bars), whereas MET significantly increased in hM4 superna-
tant (Fig. 4B, black bars). The effect of 6-AN was abolished by the presence
of MET in A375 and hM4 but not in hM1, where MET/6-AN combination
also decreased the concentration of lactate in the supernatant (Fig. 4B,
white bars). In addition, the concentration of glucose in the extracellular
Fig. 1. Cytotoxic effect of the combination ofmetformin and 6-aminonicotinamide on eight malignant melanoma cell lines. (A)Melanoma cells were treated with metformin
(MET, 5mM), 6-aminonicotinamide (6-AN, 50 μM) or a combination of bothMET/6-AN (5mM/50 μM). After 5 days of treatment, control and treated cells were subjected to
crystal violet staining. (B)Multicellularmelanoma spheroids after 14 days of treatment (40magnification). (C)Melanoma cells were treatedwith increasing concentrations of
metformin (1; 2.5; 5; 10mM)with orwithout the addition of 6-AN 50 μM for 5 days. After that, cell viability was determined by APH. Results are expressed as a percentage of
cell viability from control cells as means ± SEM of three independent experiments. Statistical analysis was performed with two-way ANOVA using Tukey's multiple
comparisons test to calculate significance (*p < .05, **p < .01 and ***p < .001). (D) The half maximal inhibitory concentration (IC50) of each curve were calculated.
Statistical analysis was performed with the extra sum-of-squares F test to compare if IC50 was different for each data set (***p < .001). (E) Mapped-surface of Loewe
from Combenefit software analysis of MET and 6-AN combinations. The concentrations of each drug are plotted along the horizontal axes, while the percentage of cells
viability is plotted on the vertical axis. A heat map represents the level of synergy (blue color) at each concentration.
M.F. Arbe et al. Translational Oncology 13 (2020) 100842medium was higher, thus indicating less consumption, than control cells
after 6-AN and MET/6-AN treatment in the supernatant of hM1 and
A375, but not in that of hM4 (Fig. 4C). We found comparable results at ex-
tracellular glucose concentration when referring glucose values to the num-
ber of viable cells (Supplementary Fig. S1). In addition, we found also
comparable results by referring lactate values to the number of viable
cells except for MET/6-AN treatment. This effect may be explained by the
fact that we measured the accumulative lactate. As this metabolite was
not present in the fresh medium, we hypothesize that during MET/6-AN
treatment lactate production was almost zero. As Met/6-AN decreased
cell viability, by referring this to viable cells, we increased the value of lac-
tate evenwhen its production was not augmented (Supplementary Fig. S1).4
We further investigated whether the glucose transporter GLUT1 was
being modulated by MET and/or 6-AN treatment. We found that the treat-
ment with 6-AN alone (A375 and hM1) or in combination with MET (hM1)
produced an increase in GLUT1 content. Notably, hM4 presented consider-
ably less GLUT1 content than A375 and hM1 cells, without considerable
changes after the treatments (Fig. 4D).
MET/6-AN increased intracellular oxidants and depolarized mitochondria
One of the most important roles of G6PDH (as the main enzyme of PPP)
is to restitute the concentration of glutathione (the most abundant soluble
antioxidant) from glutathione disulfide by the activity of the enzyme
Fig. 2. Decrease in the proliferative index, cells in S phase and PCNA expression after MET/6-AN treatment. Melanoma cells were treated with metformin (MET, 5 mM), 6-
aminonicotinamide (6-AN, 50 μM) or a combination of both (MET/6-AN). After 48 h of treatment, nuclei were stainedwith DAPI and immuno-stained with (A) amonoclonal
antiKi67 antibody to evaluate the proliferation index or (B) a monoclonal antiBrdU antibody to determine the number of cells in S phase. Images were obtained at 400
magnification. Results are expressed as means ± SEM of three independent experiments. Statistical analysis (A and B) was performed with one-way ANOVA using
Tukey's multiple comparisons test to calculate significance (*p < .05, **p < .01 and ***p < .001 respect to control treated with PBS, ○○○p < .001 respect to MET
5mM and●●●p< .001 respect to 6-AN 50 μM). (C) Representative immunoblot analysis showing the level of PCNA after 48 h treatment of two independent experiments.
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of G6PDH, we expected an increase in the levels of intracellular oxidants.
However, 6-AN as single agent was not enough to significantly increase
the levels of intracellular oxidants (Fig. 5A, gray bars). A similar situation5
was observed after MET treatment in all cell lines. In contrast, the MET/
6-AN combination increased the levels of intracellular oxidants at 48 h in
A375 and hM1, with a maximum increase after 72 h as observed by the
shift to the right of the green fluorescent abscissa (FL1) and by the
Fig. 3. Apoptosis/necrosis induced by MET/6-AN treatment. Melanoma cells were treated with metformin (MET, 5 mM), 6-aminonicotinamide (6-AN, 50 μM) or a
combination of both (MET/6-AN). (A) After 72 h of treatments, non-fixed cells were incubated with acridine orange/ethidium bromide (AO/EB) to be evaluated by
epifluorescence microscopy. The arrows on the representative images of AO/EB staining indicate the co-localization of both stains showing late apoptotic or necrotic
events (orange/red). (B) After 48 h treatment, Annexin V antibody and propidium iodide (PI, 5 μg/mL) label was detected by flow cytometry as described in M&M.
Results are expressed as dot plot graph and stacked bar chart with means of three independent experiments. (C) After 48 h treatment, the SubG0 population was
determined. Results are expressed as means ± SEM of two independent experiments. Statistical analysis was performed with one-way ANOVA using Tukey's multiple
comparisons test to calculate significance (*p < .05 and ***p < .001 respect to control treated with PBS, ○○○p < .001 respect to MET 5 mM and ●●●p < .001
respect to 6-AN 50 μM). (D) Representative image of Poly (ADP-ribose) polymerase-1 (PARP1) expression after 48 h of treatments. Values refer to the relative density of
cleaved PARP with the respective β-actin. Results are expressed as means ± SEM of two independent experiments.
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independent experiments (Fig. 5A). Conversely, hM4 cells did not show
an increase in the levels of intracellular oxidants after the treatments
(Fig. 5A).
Since mitochondria are one of the main sources of intracellular oxidants
and mitochondria depolarization could be involved in melanoma cell
death, we next studied the integrity of the mitochondrial potential after the
treatments. We found that MET did not affect the mitochondrial potential6
of melanoma cells as monotherapy at any time. Interestingly, the mitochon-
drial potential of A375 remaining cells was significantly increased 72 h
after the 6-AN and MET/6-AN treatment (Fig. 5B). On the other hand, hM1
cells presented an early depolarization at 24 h after theMET/6-AN treatment,
which was not overcome at any of the times evaluated (Fig. 5B). Finally, the
mitochondrial potential of hM4 was not significantly affected by the treat-
ments (Fig. 5B). Nevertheless,MET/6-AN treatment tended to cause earlymi-
tochondrial depolarization in all cell lines.
Fig. 4.Modulation of glycolytic parameters byMET, 6-AN or the combination of both. Melanoma cells were treated with metformin (MET, 5 mM), 6 aminonicotinamide (6-
AN, 50 μM) or a combination of both MET/6-AN (5 mM/50 μM). After 48 h of treatment, control and treated cells were subjected to determination of extracellular: (A) pH,
(B) lactate and (C) glucose. Results are expressed relative to control cells as means ± SEM of three independent experiments. Statistical analysis (A, B and C) was performed
with one-way ANOVA using Tukey's multiple comparisons test to calculate significance (*p< .05, **p< .01 and ***p< .001 respect to control treatedwith PBS,○○○p<
.001 respect toMET 5mMand●●●p< .001 respect to 6-AN 50 μM). (D) Representative image of the expression of glucose transporter 1 (Glut1). Values refer to the relative
density of Glut1 with the respective β-actin of three independent experiments.
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in cell complexity. Interestingly, we found that not onlyMET/6-AN but also
6-AN as single agent significantly increased cell complexity at 24 h, with a
maximum of effect at 72 h, being the magnitude of the effect of the combi-
nation higher than that of 6-AN as a single agent (Fig. 5C). In addition, hM4
did not increase its intracellular complexity at any time with any treatment,
in concordance with the results regarding the levels of its mitochondrial
and intracellular oxidants.
Metformin and 6-AN inhibitor increased the activity of NADPH producing
enzymes
As cell reductive power should be accurately maintained to normal cell
function, we hypothesized that other NADPH enzymatic sources may be in-
creasing their activities in order to compensate G6PDH inhibition by 6-AN.
Effectively, 6-AN treatment for 48 h increased the activity of NADP-
dependent Malic Enzyme (ME(NADP), 4-fold, p < .001) and Isocitrate De-
hydrogenase IDH enzyme (20-fold, p < .001) (Fig. 6A).Most interestingly,
MET and MET/6-AN treatment also increased (NADP-dependent) IDH ac-
tivity (10-fold and 5-fold, p< .01 and p< .05, respectively). Furthermore,
MET, 6-AN or the combination of MET/6-AN drastically increased NAD de-
pendent ME (ME(NAD), ~100-fold, p < .001).
Since MET and 6-AN were probably affecting NADPH content, we ex-
plored whether NADPH supply could reverse or at least diminish the cyto-
toxic effect of its combination. Interestingly, we found that 50 μM NADPH
was able to significantly reverseMET/6-AN effect on hM4 (Fig. 6C) but not
in A375 nor hM1 cells. Additionally, 50 μM NADH or the combination of
both, NADPH/NADH (50 μM/50 μM) was also able to produce this inhibi-
tory effect only in hM4. Since transportation of NADPH and NADH across
cell membrane remains controversial [41], we investigated the addition
of nicotinamide (NAM), a soluble precursor of its synthesis by the savage
pathway. Irrespectively of the cell line, NAM (5 mM) reversed MET/6-AN
(p < .001). Interestingly, the effect of MET/6-AN was reduced up to the7
effect of MET alone. Moreover, 6-AN but not MET cytotoxic effect was
completely reversed by NAM in hM1 (Fig. 6C).Discussion
In agreement with previous studies [5,9,42,43], our results support the
idea of bioenergetic modulation as an emerging strategy to treat cancer. In
this aspect, Arbe et al., 2017, and other groups have published exciting re-
sults about the synergistic combination of MET and 2-deoxyglucose (2DG),
a glucose analogous, on felinemammary carcinoma cells and awide variety
of different tumor cells, respectively [25,39,40]. However, only two (hM4
and hM9) out of eight human melanoma cells (25%) have shown a signifi-
cant potentiation after MET and 2DG combination (data not shown, manu-
script in progress). Remarkably, those cells were considered highly
sensitive to glycolysis inhibition by 2DG. In contrast, we didfind a synergis-
tic effect on eight out of eight melanoma cell lines (100% effectiveness,
Fig. 1) by combining MET with 6-AN, an inhibitor of G6PDH [44–46],
the first and limiting enzyme of the PPP, irrespectively of the response of
the monotherapies. These results propose a common or an interrelated
mechanism between MET signaling and the PPP, suggesting NADPH as
one of the molecules involved. Consistent with our results, down-
regulation of ME, another NADPH producing enzyme, increased MET re-
sponse in HNSCC [47]. The PPP is the second most important fate of intra-
cellular glucose after glycolysis, and supplies the requirement of anabolic
precursors [7,8]. Another aspect to take into consideration should be the
fact that G6PDH inhibition induces an increase in its substrate G6P,
which in turn, inhibits hexokinase, a key enzyme of glycolysis. This effect
could explain the decrease observed in lactate production and glucose con-
sumption after 6-AN treatment of melanoma cells (Fig. 4B). In contrast,
MET increased lactate production in hM4 and this effect was not prevented
by the addition of 6-AN. We hypothesized that these different behaviors
among melanoma cell lines may be related to their differences in glycolysis
Fig. 5. Intracellular oxidants, mitochondrial potential and cell complexity after treatment with MET, 6-AN or the combination of both. Melanoma cells were treated with
metformin (MET, 5 mM), 6-aminonicotinamide (6-AN, 50 μM) or a combination of both (MET/6-AN). After 24, 48, or 72 h of treatment, cells were incubated with
(A) DCF (2′,7′-dichlorodihydrofluorescein diacetate, intracellular oxidants) for 20 min, (B) TMRM (tetramethylrhodamine, methyl ester mitochondrial membrane
potential) for 30 min and evaluated by flow cytometry as described in M&M. (C) Cell complexity was determined from the physical parameter SSC (Side scatter) on a dot
plot graph. From each label or SSC, a representative overlay histogram is shown at 48 h of treatment. Results are expressed as means ± SEM of three independent
experiments. Statistical analysis was performed with one-way ANOVA using Tukey's multiple comparisons test to calculate significance (*p < .05, **p < .01 and ***p <
.001 respect to control treated with PBS,○○○p < .001 respect to MET 5 mM and ●●●p < .001 respect to 6-AN 50 μM).
M.F. Arbe et al. Translational Oncology 13 (2020) 100842dependence, being hM4 less glycolytic than hM1 and A375 as suggested by
our compelling results (unpublished data, manuscript in progress).
During MET/6-AN treatment but not MET alone, A375 and hM1 cells
increased the production of reactive oxygen species (ROS) within the first8
48 h. Accordingly with Choi et al., 2014 metformin as monotherapy signif-
icantly increases ROS and decreases GSH levels during glucose deprivation
[26]. We hypothesized that 6-AN not only may be mimicking a glucose-
free-like condition but also decreasing NADPH which in turn affects GSH
Fig. 6. Increased activity of NADPH producing enzymes byMET and 6-AN treatments. Melanoma cells were treated with metformin (MET, 5 mM), 6-aminonicotinamide (6-
AN, 50 μM) or a combination of both (MET/6-AN). After 48 h of treatment, cells were lysed, and enzyme activity was measured as described in M&M. (A) Results are
expressed as mean activity ± SEM of two independent experiments. Statistical analysis was performed with one-way ANOVA using Tukey's multiple comparisons test to
calculate significance (*p < .05, **p < .01 and ***p < .001 respect to control treated with PBS, ○○○p < .001 respect to MET 5 mM, ■■■p < .001 respect to MET/6-
AN). (B) Representative image of the effect of MET and 6-AN effect. (C) Melanoma cells were treated with metformin (MET, 5 mM), 6-aminonicotinamide (6-AN, 50 μM)
and a combination of both (MET/6-AN) with or without the addition of Nicotinamide Adenine Dinucleotide Phosphate Hydrate (NADPH, 50 μM). After 5 days of
treatment, control and treated cells were subjected to the acid phosphatase assay as described in M&M. Results are expressed as means ± SEM of four independent
experiments. Statistical analysis was performed with two-way ANOVA using Tukey's multiple comparisons test to calculate significance (***p < .001).
M.F. Arbe et al. Translational Oncology 13 (2020) 100842levels and the antioxidant capacity even at high glucose condition (all the
experiments have been performed under high glucose condition). In accor-
dance, we found that MET and 6-AN increased IDH activity probably to ab-
rogate oxidative stress.Moreover, the inhibition of G6PDH, themain source
of NADPH, promoted both IDH (NADP-dependent) and ME (NADP-depen-
dent) activity increase (Fig. 6A and B). Probably, by means of these com-
pensatory activities, 6-AN-treated melanoma cells did not present ROS
increase (Fig. 4B). In contrast, the increase in the activities of IDH(NADP)
and ME(NADP) was not enough for reversing the reductive power impair-
ment displayed by MET, thus promoting almost 50% of A375 cells death.
This disability was even worst during MET/6-AN combination, thus pro-
moting over 80% of A375 cells death (Figs. 1, 6A and B). Oxidative stress
was accompanied by a hyperpolarization of the mitochondria in remaining
A375 cells probably in an attempt to resist cell death, as it has been previ-
ously reported to other antitumor therapies [49]. In contrast with A375,
the mitochondrial potential of hM1 significantly decreased and did not hy-
perpolarize during the time evaluated. Simultaneously, this effect was ac-
companied by an increase in intracellular complexity in both cell lines,
probably due to an autophagy process as previously described during the
combination of MET and 2DG by Arbe et al., 2017 [25] and others [40]. In-
deed, our preliminary results in canine and feline melanoma cells and
human glioblastoma cells also support this hypothesis (data not shown).9
Ki67 immunostaining and BrdUr assay allowed observing that MET/6-
AN decreased the proliferation index in all cell lines, especially in hM1,
where 6-AN had also a low but significant effect as a monotherapy
(Fig. 2). We also found that hM1 displayed a higher γH2AX immunostain-
ing than A375 (Supplementary Fig. S2). Among its different activities,
PARP may be displaying a protective role (as part of the DNA repair re-
sponse) during the cytotoxic effect of MET/6-AN, especially in hM1 cells,
where not only cleaved PARP but also its full-length protein was higher
than in the other tested cells (Fig. 3D). Furthermore, hM1 presented the
highest Annexin V positivity in agreement with the increase in cleaved
PARP levels (Fig. 3). On the other hand, MET/6-AN was also a cytotoxic
treatment that promoted both apoptotic and necrotic events (Figs. 2 and
3). However, flow cytometry analysis of cell death denoted a notorious in-
crease in late apoptotic but not in necrotic events. This indicates that cells
from AO/BET staining and those shown as SubG0 population (Fig. 5B red
and C respectively) were probably secondary to apoptotic processes. Taking
into account the differences between hM4 and the other twomelanoma cell
lines after MET/6-AN treatment in terms of ROS production, mitochondrial
potential and cell complexity, our results suggest that the particular behav-
ior of hM4 could be due to a less glycolytic phenotype as it has been sug-
gested above. Although this hypothesis remains to be fully investigated,
we found that hM4 presented less glucose consumption and GLUT1
Fig. 7. Suggested metabolic changes displayed by MET in combination with 6-AN. Inhibition of G6PDH enhances MET cytotoxicity probably through decreasing cell
reductive capacity. While MET alone increases glucose consumption and lactate production, MET/6-AN combination blocks this compensatory mechanism. In addition,
during MET treatment, the induction of IDH(NADP) activity favors to decrease oxidative stress. In contrast, MET/6-AN treated cells may not overcome redox imbalance
driving melanoma cells to increased apoptosis and necrosis.
M.F. Arbe et al. Translational Oncology 13 (2020) 100842content, which were not altered by the 6-AN or MET/6-AN treatment
(Fig. 4C and D).
As it has been recently reviewed by Jaune and Rocchi [50], MET antitu-
mor activity is being extensively evaluated (more than 300 clinical trials,
ClinicalTrials.gov) in different types of cancer. Less is knownabout the ther-
apeutic opportunities of inhibiting the PPP [9].
Here, we demonstrate, for the first time, that G6PDH inhibition potenti-
ates MET cytotoxicity leading to increased apoptotic/necrotic events, de-
creased growth and survival of melanoma cells, accompanied by a redox
imbalance probably due to a large reductive power impairment (Fig. 7).
Ourwork suggests that G6PDH inhibition represents a potential therapeutic
strategy to potentiate MET antitumoral effects in melanoma.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.tranon.2020.100842.
Author contributions statement
ArbeMF:Methodology, Conceptualization, Investigation, Formal analy-
sis Visualization and Writing - Review & Editing.
Agnetti L: Methodology, Visualization.
Breininger E: Methodology, Formal analysis.
Finocchiaro LME: Writing - Review & Editing and Funding acquisition.
Glikin GC: Writing - Review & Editing and Funding acquisition.
Villaverde MS: Conceptualization, Investigation, Formal analysis, Visu-
alization, Writing - Original Draft, Writing - Review & Editing, Supervision
and Funding acquisition.
Declaration of competing interest
The authors declare that they have no known competing financial inter-
ests or personal relationships that could have appeared to influence the
work reported in this paper.
Acknowledgements
We thank Graciela B. Zenobi for technical advice and assistance. This
work was supported by Agencia Nacional de Promoción Científica y
Tecnológica (PICT 2014-1247 and PICT 2012-1738, Préstamo BID) and
by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET,
D3646/14 and PIP 112 201101 00627). GCG, LMEF, and MSV are investi-
gators and MFA, and LA are fellows of CONICET, Argentina.10References
[1] A.M.M. Eggermont, A. Spatz, C. Robert, Cutaneous melanoma, Lancet, Lancet Publish-
ing Group 2014, pp. 816–827, https://doi.org/10.1016/S0140-6736(13)60802-8.
[2] J.S. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, M. Yellin, J. Snively, E. Hersh,
Phase I/II study of ipilimumab for patients with metastatic melanoma, J. Clin. Oncol.
26 (2008) 5950–5956, https://doi.org/10.1200/JCO.2008.16.1927.
[3] O. Warburg Berlin-Dahlem, The Metabolism of Carcinoma Cells, n.d.
[4] A.M. Otto, Warburg effect(s)—a biographical sketch of Otto Warburg and His impacts
on tumor metabolism, Cancer Metab. (2016)https://doi.org/10.1186/s40170-016-
0145-9.
[5] S. Granja, C. Pinheiro, R.M. Reis, O. Martinho, F. Baltazar, Send Orders for Reprints to
reprints@benthamscience.ae Glucose Addiction in Cancer Therapy: Advances and
Drawbacks, 2015.
[6] G. Kroemer, J. Pouyssegur, Tumor cell metabolism: cancer's Achilles' heel, Cancer Cell
13 (2008) 472–482, https://doi.org/10.1016/j.ccr.2008.05.005.
[7] A. Stincone, A. Prigione, T. Cramer, M.M.C. Wamelink, K. Campbell, E. Cheung, V. Olin-
Sandoval, N.-M. Grüning, A. Krüger, M.T. Alam, M.A. Keller, M. Breitenbach, K.M.
Brindle, J.D. Rabinowitz, M. Ralser, The return of metabolism: biochemistry and phys-
iology of the pentose phosphate pathway HHS public access, Biol. Rev. Camb. Philos.
Soc. 90 (2015) 927–963, https://doi.org/10.1111/brv.12140.
[8] K.C. Patra, N. Hay, The pentose phosphate pathway and cancer, Trends Biochem. Sci.
(2014)https://doi.org/10.1016/j.tibs.2014.06.005.
[9] L. Mele, F. Paino, F. Papaccio, T. Regad, D. Boocock, P. Stiuso, A. Lombardi, D. Liccardo,
G. Aquino, A. Barbieri, C. Arra, C. Coveney, M. La Noce, G. Papaccio, M. Caraglia, V.
Tirino, V. Desiderio, A new inhibitor of glucose-6-phosphate dehydrogenase blocks pen-
tose phosphate pathway and suppresses malignant proliferation and metastasis in vivo
article, Cell Death Dis. (2018)https://doi.org/10.1038/s41419-018-0635-5.
[10] P. Jiang, W. Du, M.Wu, Regulation of the pentose phosphate pathway in cancer, Protein
Cell. (2014)https://doi.org/10.1007/s13238-014-0082-8.
[11] D. Catanzaro, E. Gaude, G. Orso, C. Giordano, G. Guzzo, A. Rasola, E. Ragazzi, L.
Caparrotta, C. Frezza, M. Montopoli, Inhibition of glucose-6-phosphate dehydrogenase
sensitizes cisplatin-resistant cells to death, Oncotarget 6 (2015) 30102–30114, https://
doi.org/10.18632/oncotarget.4945.
[12] S. Del Barco, A. Vazquez-Martin, S. Cufí, C. Oliveras-Ferraros, J. Bosch-Barrera, J.
Joven, B. Martin-Castillo, J.A. Menendez, Metformin: multi-faceted protection
against cancer, Oncotarget 2 (2011) 896–917, https://doi.org/10.18632/
oncotarget.387.
[13] R.T. Chlebowski, A. McTiernan, J. Wactawski-Wende, J.A.E. Manson, A.K. Aragaki, T.
Rohan, E. Ipp, V.G. Kaklamani, M. Vitolins, R. Wallace, M. Gunter, L.S. Phillips, H.
Strickler, K. Margolis, D.M. Euhus, Diabetes, metformin, and breast cancer in postmen-
opausal women, J. Clin. Oncol. 30 (2012) 2844–2852, https://doi.org/10.1200/JCO.
2011.39.7505.
[14] F. Ochoa-Gonzalez, A.R. Cervantes-Villagrana, J.C. Fernandez-Ruiz, H.S. Nava-Ramirez,
A.C. Hernandez-Correa, J.A. Enciso-Moreno, J.E. Castañeda-Delgado, Metformin in-
duces cell cycle arrest, reduced proliferation, wound healing impairment in vivo and
is associated to clinical outcomes in diabetic foot ulcer patients, PLoS One 11 (2016)
https://doi.org/10.1371/journal.pone.0150900.
[15] Q. Guo, Z. Liu, L. Jiang, M. Liu, J. Ma, C. Yang, L. Han, K. Nan, X. Liang, Metformin in-
hibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent
activation of adenosine monophosphate-activated protein kinase, Mol. Med. Rep. 13
(2016) 2590–2596, https://doi.org/10.3892/mmr.2016.4830.
M.F. Arbe et al. Translational Oncology 13 (2020) 100842[16] X. Wu, H. Yeerna, Y. Goto, T. Ando, V.H. Wu, X. Zhang, Z. Wang, P. Amornphimoltham,
A.N. Murphy, P. Tamayo, Q. Chen, S.M. Lippman, J.S. Gutkind, Metformin inhibits pro-
gression of head and neck squamous cell carcinoma by acting directly on carcinoma ini-
tiating cells, Cancer Res. (2019)https://doi.org/10.1158/0008-5472.CAN-18-3525
canres.3525.2018.
[17] K.H. Kim, Y.T. Jeong, S.H. Kim, H.S. Jung, K.S. Park, H.Y. Lee, M.S. Lee, Metformin-
induced inhibition of the mitochondrial respiratory chain increases FGF21 expression
via ATF4 activation, Biochem. Biophys. Res. Commun. 440 (2013) 76–81, https://
doi.org/10.1016/j.bbrc.2013.09.026.
[18] X. Wang, K. Chen, Y. Yu, Y. Xiang, J.H. Kim, W. Gong, J. Huang, G. Shi, Q. Li, M. Zhou,
T. Sayers, P. Tewary, B. Gao, J.M. Wang, Metformin Sensitizes Lung Cancer Cells to
Treatment by the Tyrosine Kinase Inhibitor Erlotinib, n.d. www.impactjournals.com/
oncotarget (accessed November 27, 2019).
[19] D. Martin, M.C. Abba, A.A. Molinolo, L. Vitale-Cross, Z. Wang, M. Zaida, N.C. Delic, Y.
Samuels, G.J. Lyons, J.S. Gutkind, The head and neck cancer cell oncogenome: a plat-
form for the development of precision molecular therapies, Oncotarget 5 (2014)
1–18, https://doi.org/10.18632/oncotarget.2417.
[20] H. Montaudié, M. Cerezo, P. Bahadoran, C. Roger, T. Passeron, L. Machet, J.-P. Arnault,
L. Verneuil, E. Maubec, F. Aubin, F. Granel, D. Giacchero, V. Hofman, J.-P. Lacour, A.
Maryline, R. Ballotti, S. Rocchi, Metformin monotherapy in melanoma: a pilot, open-
label, prospective, and multicentric study indicates no benefit, Pigment Cell Melanoma
Res. 30 (2017) 378–380, https://doi.org/10.1111/pcmr.12576.
[21] M.A. Pierotti, F. Berrino, M. Gariboldi, C. Melani, A. Mogavero, T. Negri, P. Pasanisi, S.
Pilotti, Targeting metabolism for cancer treatment and prevention: metformin, an old
drug with multi-faceted effects, Oncogene. 32 (2013) 1475–1487, https://doi.org/10.
1038/onc.2012.181.
[22] S. Schoors, U. Bruning, R. Missiaen, K.C.S. Queiroz, Europe PMC Funders Group, Fatty
acid carbon is essential for dNTP synthesis in endothelial cells, 520 (2015) 192–197,
https://doi.org/10.1038/nature14362.Fatty.
[23] E.A.I.F. Queiroz, S. Puukila, R. Eichler, S.C. Sampaio, H.L. Forsyth, S.J. Lees, A.M.
Barbosa, R.F.H. Dekker, Z.B. Fortes, N. Khaper, Metformin induces apoptosis and cell
cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer
cells, PLoS One 9 (2014)https://doi.org/10.1371/journal.pone.0098207.
[24] S.M. Samuel, E. Varghese, P. Kubatka, C.R. Triggle, D. Büsselberg, Metformin: the an-
swer to cancer in a flower? Current knowledge and future prospects of metformin as
an anti-cancer agent in breast cancer, Biomolecules. 9 (2019) 846, https://doi.org/10.
3390/biom9120846.
[25] M.F. Arbe, C. Fondello, L. Agnetti, G.M. Álvarez, M.N. Tellado, G.C. Glikin, L.M.E.
Finocchiaro, M.S. Villaverde, Inhibition of bioenergetic metabolism by the combination
of metformin and 2-deoxyglucose highly decreases viability of feline mammary carci-
noma cells, Res. Vet. Sci. 114 (2017)https://doi.org/10.1016/j.rvsc.2017.07.035.
[26] Y.W. Choi, I.K. Lim, Sensitization of metformin-cytotoxicity by dichloroacetate via
reprogramming glucose metabolism in cancer cells, Cancer Lett. 346 (2014) 300–308,
https://doi.org/10.1016/j.canlet.2014.01.015.
[27] C. Fondello, L. Agnetti, M.S. Villaverde, M. Simian, G.C. Glikin, L.M.E. Finocchiaro, The
combination of bleomycin with suicide or interferon-β gene transfer is able to efficiently
eliminate human melanoma tumor initiating cells, Biomed. Pharmacother. 83 (2016)
https://doi.org/10.1016/j.biopha.2016.06.038.
[28] M.V. Lopez, D.L. Viale, E.G.A. Cafferata, A.I. Bravo, C. Carbone, D. Gould, Y.
Chernajovsky, O.L. Podhajcer, Tumor associated stromal cells play a critical role on
the outcome of the oncolytic efficacy of conditionally replicative adenoviruses, PLoS
One 4 (2009), e5119. https://doi.org/10.1371/journal.pone.0005119.
[29] S. Gnjatic, Z. Cai, M. Viguier, S. Chouaib, J.G. Guillet, J. Choppin, Accumulation of the
p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by
breast carcinomas and melanomas, J. Immunol. 160 (1998) 328–333.
[30] J.M. Kelm, N.E. Timmins, C.J. Brown, M. Fussenegger, L.K. Nielsen, Method for
generation of homogeneous multicellular tumor spheroids applicable to a wide va-
riety of cell types, Biotechnol. Bioeng. 83 (2003) 173–180, https://doi.org/10.
1002/bit.10655.
[31] M.F. Arbe, C. Fondello, L. Agnetti, G.M. Álvarez, M.N. Tellado, G.C. Glikin, L.M.E.
Finocchiaro, M.S. Villaverde, Inhibition of bioenergetic metabolism by the combination
of metformin and 2-deoxyglucose highly decreases viability of feline mammary carci-
noma cells, Res. Vet. Sci. 114 (2017) 461–468, https://doi.org/10.1016/j.rvsc.2017.
07.035.11[32] K. Saotome, H. Morita, M. Umeda, Cytotoxicity test with simplified crystal violet stain-
ing method using microtitre plates and its application to injection drugs, Toxicol. in
Vitro 3 (1989) 317–321, https://doi.org/10.1016/0887-2333(89)90039-8.
[33] I.V. Bijnsdorp, E. Giovannetti, G.J. Peters, Analysis of Drug Interactions, Humana Press,
2011 421–434, https://doi.org/10.1007/978-1-61779-080-5_34.
[34] T.C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: the combined
effects of multiple drugs or enzyme inhibitors, Adv. Enzym. Regul. 22 (1984) 27–55,
https://doi.org/10.1016/0065-2571(84)90007-4.
[35] G.Y. Di Veroli, C. Fornari, D. Wang, S. Verine Mollard, J.L. Bramhall, F.M. Richards, D.I.
Jodrell, Combenefit: An Interactive Platform for the Analysis and Visualization of Drug
Combinations, (n.d.). doi:https://doi.org/10.1093/bioinformatics/btw230.
[36] L.M.E. Finocchiaro, G.C. Glikin, Intracellular melatonin distribution in cultured cell
lines, J. Pineal Res. 24 (1998) 22–34, https://doi.org/10.1111/j.1600-079X.1998.
tb00362.x.
[37] D.E. Brooks, Activity and androgenic control of enzymes associated with the tricarbox-
ylic acid cycle, lipid oxidation and mitochondrial shuttles in the epididymis and epidid-
ymal spermatozoa of the rat, Biochem. J. 174 (1978) 741–752, https://doi.org/10.
1042/bj1740741.
[38] E. Breininger, D. Dubois, V.E. Pereyra, P.C. Rodriguez, M.M. Satorre, P.D. Cetica, Partic-
ipation of phosphofructokinase, malate dehydrogenase and isocitrate dehydrogenase in
capacitation and acrosome reaction of boar spermatozoa, Reprod. Domest. Anim. 52
(2017) 731–740, https://doi.org/10.1111/rda.12973.
[39] J.-H. Cheong, E.S. Park, J. Liang, J.B. Dennison, D. Tsavachidou, C. Nguyen-Charles, K.
Wa Cheng, H. Hall, D. Zhang, Y. Lu, M. Ravoori, V. Kundra, J. Ajani, J.-S. Lee, W. Ki
Hong, G.B. Mills, Dual inhibition of tumor energy pathway by 2-deoxyglucose and met-
formin is effective against a broad spectrum of preclinical cancer models, Mol. Cancer
Ther. (2011)https://doi.org/10.1158/1535-7163.MCT-11-0497.
[40] I. Ben Sahra, K. Laurent, S. Giuliano, F. Larbret, G. Ponzio, P. Gounon, Y. Le Marchand-
Brustel, S. Giorgetti-Peraldi, M. Cormont, C. Bertolotto, M. Deckert, P. Auberger, J.F.
Tanti, F. Bost, Targeting cancer cell metabolism: the combination of metformin and 2-
deoxyglucose induces p53-dependent apoptosis in prostate cancer cells, Cancer Res.
(2010)https://doi.org/10.1158/0008-5472.CAN-09-2782.
[41] W. Xiao, R.-S. Wang, D.E. Handy, J. Loscalzo, NAD(H) and NADP(H) redox couples and
cellular energy metabolism, Antioxid. Redox Signal. 28 (2018) 251–272, https://doi.
org/10.1089/ars.2017.7216.
[42] R.C. Sun, P.G. Board, A.C. Blackburn, Targeting metabolism with arsenic trioxide and
dichloroacetate in breast cancer cells, Mol. Cancer (2011)https://doi.org/10.1186/
1476-4598-10-142.
[43] C. De Santo, S. Booth, A. Vardon, A. Cousins, V. Tubb, T. Perry, B. Noyvert, A. Beggs, M.
Ng, C. Halsey, P. Kearns, P. Cheng, F. Mussai, The arginine metabolome in acute lym-
phoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-
100, Int. J. Cancer 142 (2018) 1490–1502, https://doi.org/10.1002/ijc.31170.
[44] L. Poulain, P. Sujobert, F. Zylbersztejn, S. Barreau, L. Stuani, M. Lambert, T.L. Palama,
V. Chesnais, High mTORC1 Activity Drives Glycolysis Addiction and Sensitivity to
G6PD Inhibition in Acute Myeloid Leukemia Cells, 2017 2326–2335, https://doi.org/
10.1038/leu.2017.81.
[45] Y. Sun, X. Gu, E. Zhang, M.A. Park, A.M. Pereira, S. Wang, T. Morrison, C. Li, J. Blenis,
V.H. Gerbaudo, E.P. Henske, J.J. Yu, Estradiol promotes pentose phosphate pathway ad-
diction and cell survival via reactivation of Akt in mTORC1 hyperactive cells, Cell Death
Dis. 5 (2014), e1231. https://doi.org/10.1038/cddis.2014.204.
[46] P.K. Sharma, R. Varshney, 2-Deoxy-D-glucose and 6-aminonicotinamide-mediated Nrf2
down regulation leads to radiosensitization of malignant cells via abrogation of GSH-
mediated defense, Free Radic. Res. 46 (2012) 1446–1457, https://doi.org/10.3109/
10715762.2012.724771.
[47] S.H. Woo, L.P. Yang, H.-C. Chuang, A. Fitzgerald, H.-Y. Lee, C. Pickering, J.N. Myers,
H.D. Skinner, Down-regulation of malic enzyme 1 and 2: sensitizing head and neck
squamous cell carcinoma cells to therapy-induced senescence, 2015https://doi.org/
10.1002/hed.24129.
[49] M.S. Villaverde, M.L. Gil-Cardeza, G.C. Glikin, L.M.E. Finocchiaro, Interferon-Β
lipofection II. Mechanisms involved in cell death and bystander effect induced by cat-
ionic lipid-mediated interferon-Β gene transfer to human tumor cells, Cancer Gene
Ther. 19 (2012)https://doi.org/10.1038/cgt.2012.19.
[50] E. Jaune, S. Rocchi, Metformin: focus on melanoma, Front. Endocrinol. (Lausanne) 9
(2018)https://doi.org/10.3389/fendo.2018.00472.
